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Subarachnoid hemorrhage (SAH) carries a 50% mortality rate. The extravasated
erythrocytes that surround the brain contain heme, which, when released from damaged red
blood cells, functions as a potent danger molecule that induces sterile tissue injury and
organ dysfunction. Free heme is metabolized by heme oxygenase (HO), resulting in the
generation of carbon monoxide (CO), a bioactive gas with potent immunomodulatory
capabilities. Here, using a murine model of SAH, we demonstrated that expression of the
inducible HO isoform (HO-1, encoded by Hmox1) in microglia is necessary to attenuate
neuronal cell death, vasospasm, impaired cognitive function, and clearance of cerebral
blood burden. Initiation of CO inhalation after SAH rescued the absence of microglial HO-1
and reduced injury by enhancing erythrophagocytosis. Evaluation of correlative human data
revealed that patients with SAH have markedly higher HO-1 activity in cerebrospinal fluid
(CSF) compared with that in patients with unruptured cerebral aneurysms. Furthermore,
cisternal hematoma volume correlated with HO-1 activity and cytokine expression in the
CSF of these patients. Collectively, we found that microglial HO-1 and the generation of CO
are essential for effective elimination of blood and heme after SAH that otherwise leads to
neuronal injury and cognitive dysfunction. Administration of CO may have potential as a
therapeutic modality in patients with ruptured cerebral aneurysms.
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Introduction
Subarachnoid hemorrhage (SAH) leads to neuronal injury and 
cognitive impairment following heme-induced cerebral inflam-
mation, which takes place in response to the accumulation of 
heme-containing blood components, particularly hemoglobin-
saturated erythrocytes. The heme oxygenase (HO) enzymes are 
responsible for degrading heme into biliverdin, iron, and carbon 
monoxide (CO). There are 2 isoforms of HO: HO-1 is the ubiqui-
tously expressed, inducible isoform, while HO-2 is constitutively 
expressed in the brain, endothelium, and testes. HO-1 is a cyto-
protective molecule critical in maintaining cellular homeostasis 
and, when absent, results in exaggerated and unfettered inflam-
mation. In contrast, induction of HO-1 exerts potent protective 
effects in numerous preclinical disease models including sepsis, 
trauma, vascular proliferative disease, acute lung and liver injury, 
and cancer (1–5). A number of recent reports have demonstrated 
the benefits of HO-1 in the CNS, including the eye (6) and brain 
(7–12). In the brain, expression of each HO isoform follows a dis-
tinct spatial and cell-specific distribution pattern. HO-2 is con-
stitutively expressed in neuronal cells, and expression levels are 
not changed by stress such as ischemia or hemorrhagic injury 
(13, 14). In contrast, HO-1 is sparsely expressed in the uncompro-
mised brain but strongly upregulated in glial cells following injury 
(13–19). A role for HO-1 in response to cerebral injury remains 
unclear but likely relates to the acute phase response and the gen-
eration of one or more of its bioactive products including CO, iron, 
and the bile pigments biliverdin and bilirubin. Exogenous applica-
tion of low doses of CO can recapitulate the cytoprotective effects 
of HO-1 induction (20–28), but few studies have demonstrated 
that CO can actually substitute for the absence of HO-1 in a cell 
type–specific fashion, particularly in the brain. Only a few reports 
have examined the protective effects of CO on neuronal cells in 
vitro and in vivo (29–32). In fact, the majority of reports contend 
that CO is potently neurotoxic, resulting in memory loss, confu-
sion, and even flu-like symptoms thought to arise in part from neu-
ronal cell death. In direct contrast to this dogma, we provide com-
pelling data demonstrating that CO can protect the brain, even 
when exposure is initiated after blood has accumulated within the 
subarachnoid space. The mechanism involves, in part, increased 
phagocytic activity of microglia to clear the erythrocyte burden. 
Moreover, when HO-1 is absent in microglia, there is impaired 
phagocytosis, increased neuronal injury, and cognitive dysfunc-
tion, all of which can be rescued with administration of CO.
Results
Pharmacological inhibition of HO leads to aggravated neuronal injury 
after SAH. We first characterized the role of HO in neuronal injury 
following SAH by pharmacologically blocking HO with tin pro-
toporphyrin-IX (SnPP) in WT mice. We analyzed cerebral vaso-
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(Figure 2, A and B), cohorts of LyzM-Cre Hmox1fl/fl and Hmox1fl/fl mice 
were subjected to SAH, as described above. As was observed with 
pharmacologic inhibition, LyzM-Cre Hmox1fl/fl mice showed signifi-
cantly increased vasospasm and neuronal apoptosis compared with 
Hmox1fl/fl control mice after SAH, which corresponded with signifi-
cantly impaired cognitive function in the Barnes maze test (Figure 
2, C–H). Again, no difference in task learning was observed prior to 
SAH (Supplemental Figure 1, C and D).
LyzM-Cre Hmox1fl/fl mice express Cre recombinase in all cells 
of myeloid lineage. Therefore, to distinguish between the role of 
HO-1 in brain-resident microglia versus peripheral myeloid cells 
that might infiltrate the brain following SAH and contribute to the 
effects seen, we transplanted BM from HO-1–competent animals 
into LyzM-Cre Hmox1fl/fl mice prior to SAH. The requisite total-
body irradiation necessary to reconstitute BM compromises the 
blood-brain barrier (BBB) and permits infiltration of peripheral 
leukocytes (33). Using a lead helmet and transplanting BM from 
Cx3cr1-GFP mice, we observed no leukocyte infiltration into 
the brain after irradiation compared with transplanted animals 
irradiated without the lead helmet (Supplemental Figure 2). We 
concluded that head shielding prevented BBB compromise. This 
methodology thus enabled us to generate chimeric mice contain-
ing peripheral HO-1–competent myeloid lineage cells, while simul-
spasm, neuronal apoptosis, and cognitive function over a period 
of 7 days following SAH. WT mice subjected to SAH (WT SAH) 
treated with SnPP showed more severe vasospasm compared with 
WT SAH mice treated with vehicle (Figure 1, A and B). HO inhibi-
tion also significantly increased neuronal cell death in the dentate 
gyrus (DG) and cortex by 62% and 103%, respectively (Figure 1, C 
and D). Assessment of spatial memory function using the Barnes 
maze test showed that animals subjected to HO inhibition had 
an increased error rate, with greater delay in finding the goal box 
compared with controls (Figure 1, E and F). Importantly, no dif-
ference in task learning was observed prior to SAH (Supplemental 
Figure 1, A and B; supplemental material available online with this 
article; doi:10.1172/JCI78443DS1).
SAH-induced neuronal injury and the role of HO-1 in microglia. 
SnPP administration inhibited both HO-1 and HO-2 globally and 
therein carries some degree of nonspecificity. We therefore used a 
more rigorous genetic approach to specifically test the importance 
of HO-1 in response to SAH. Since HO-1 is primarily upregulated in 
microglia following neuronal injury (13, 14, 16), we generated LyzM- 
Cre Hmox1fl/fl mice, in which HO-1 is specifically deleted in cells 
expressing lysozyme, including microglia (Figure 2). After confirm-
ing the absence of HO-1 in cultured primary microglia isolated from 
LyzM-Cre Hmox1fl/fl, but not in microglia from Hmox1fl/fl control mice 
Figure 1. Aggravated neuronal injury after 
SAH due to HO inhibition with SnPP IX. (A) 
Representative (n = 6) H&E-stained cross 
sections of the MCA 7 days after SAH in 
animals treated with saline or the HO inhib-
itor SnPP (original magnification, ×40). (B) 
Quantification of MCA vasospasm, defined 
as the quotient of LR and WL. P = 0.147 
for SAH plus saline versus SAH plus SnPP 
(2-tailed Student’s t test; n = 6). (C) Repre-
sentative images (original magnification, 
×20; n = 6) from TUNEL staining (red) of the 
DG and cortex of mice that received SAH 
plus saline or SnPP treatment 7 days after 
injury. Nuclei were counterstained with 
Hoechst 33258 (blue). (D) Quantification of 
TUNEL-positive cells per microscopic field 
in the designated brain regions. *P = 0.0413 
(DG) and **P = 0.015 (cortex) for SAH plus 
saline versus SAH plus SnPP (2-tailed 
Student’s t test; n = 6). (E) Number of total 
errors in spatial memory function by Barnes 
maze assessment. Graph shows test 
results on the days after spatial reversal.  
*P = 0.0071 (day 0), **P < 0.0001 (day 1), 
***P < 0.0001 (day 2), and #P = 0.0007  
(day 3) for SAH plus saline versus SAH 
plus SnPP (2-way ANOVA; n = 9). (F) Total 
latency in seconds for spatial memory  
function testing by Barnes maze test.  
*P < 0.0001 (days 0–3) for SAH plus saline 
versus SAH plus SnPP (2-way ANOVA; n = 9).
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showed a significantly greater vasospasm response and neu-
ronal apoptosis with spatial memory function impairment com-
pared with that seen in control chimeric mice (MG-Hmox1+/+ 
MY-Hmox1+/+) (Figure 3, C–H). On the basis of these results, we 
concluded that the phenotype observed in LyzM-Cre Hmox1fl/fl 
mice was principally due to HO-1 deficiency in microglia and 
that HO-1 expression in peripheral cells of the myeloid lineage 
contribute little to SAH-induced injury.
We next tested whether HO-1 expression in any other glial 
cells of the brain participated in SAH-induced injury. Mice with 
neuron- and astrocyte-specific HO-1 deletion (Nes-Cre Hmox1fl/fl), 
unlike LyzM-Cre Hmox1fl/fl mice, did not display increased neu-
taneously maintaining HO-1–deficient microglia. Importantly, 
head shielding not only prevented cerebral leukocyte infiltration 
before SAH, but also after SAH (Figure 3, A and B), indicating that 
infiltration of peripheral myeloid cells into the brain is likely not 
directly involved in SAH-induced neuronal inflammation and 
injury, although further quantitative experiments are required.
Using the methodology described above, we next trans-
planted BM from HO-1–competent animals (MY-Hmox1+/+) into 
irradiated LyzM-Cre Hmox1fl/fl (MG-Hmox1–/–) and Hmox1fl/fl 
(MG-Hmox1+/+) control mice with head shielding and subjected 
them to SAH 1 month after BM transplant. One week after 
SAH, LyzM-Cre Hmox1fl/fl chimeras (MG-Hmox1–/– MY-Hmox1+/+) 
Figure 2. Role of microglial HO-1 in 
neuronal injury after SAH. (A) PMG 
isolated from brains of Hmox1fl/fl or 
LyzM-Cre Hmox1fl/fl mice stained for 
IBA1 (green) and nuclear counterstain-
ing with Hoechst 33258 (blue). DsRed 
expression (red; yellow for red/green 
merged) was exclusively initiated when 
the LoxP site–flanked Hmox1 gene 
was deleted in cells with LyzM-Cre 
gene expression (right panel, original 
magnification, ×40; n = 3). (B) HO-1 
protein analyzed by Western blotting 
in PMG from brains of Hmox1fl/fl control 
or LyzM-Cre Hmox1fl/fl mice with or 
without red blood cell exposure (n = 3). 
(C) Representative (n = 6) H&E-stained 
cross sections of the MCA after SAH in 
Hmox1fl/fl and LyzM-Cre Hmox1fl/fl mice 
(original magnification, ×40). (D) Quan-
tification of MCA vasospasm, defined 
as the quotient of LR and WL.  
*P = 0.018 (2-tailed Student’s t test; 
n = 6). (E and F) Quantification of 
TUNEL-positive cells per microscopic 
field in the DG (E) and cortex (F).  
*P = 0.0043 (E) and **P = 0.0412 (F) 
(2-tailed Student’s t test; n = 6).  
(G) Number of total errors in spatial  
memory function by Barnes maze 
assessment. *P = 0.0071 (day 1) and  
**P = 0.0123 (day 3) (2-way ANOVA;  
n = 9). (H) Total latency in seconds for 
spatial memory function by Barnes 
maze assessment. *P = 0.0033 (day 0),  
**P = 0.0345 (day 1), ***P = 0.0021 
(day 2), and #P = 0.0006 (day 3) (2-way 
ANOVA; n = 9). (I) Representative MR 
images (n = 3) of mice with intracranial 
injection of gadopentetate dimeglu-
mine–labeled blood. (J) Quantification 
of radiographically assessed hematoma 
volume. *P = 0.0184 (2-tailed Student’s 
t test; n = 3).
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our mouse model of SAH, we next investigated the role of HO-1 
in patients with aneurysmal SAH. We enrolled 11 patients with 
SAH (Figure 5A) and measured HO-1 expression over time in both 
the cerebrospinal fluid (CSF) and peripheral blood. We observed 
a time-dependent increase in HO-1 expression in the CSF, peak-
ing 7 days after rupture, that was not observed in patients with 
unruptured cerebral aneurysms. HO-1 expression correlated with 
the amount of cisternal hematoma volume (CHV), as well as CSF 
bilirubin levels, an indirect marker of HO catalytic activity (Figure 
5, B–E). HO-1 expression in peripheral blood leukocytes of SAH 
patients showed different kinetics, with peak expression occur-
ring on day 1 versus controls and expression remaining elevated 
through day 7 (Figure 5F). We further investigated inflammatory 
markers in the CSF of SAH patients and found a sustained ele-
ronal injury or memory impairment compared with Hmox1fl/fl con-
trol mice (Figure 4). Therefore, we concluded that HO-1 expres-
sion in astrocytes and neurons was not involved in neuronal injury 
or cognitive impairment after SAH.
With evidence that microglial HO-1 was critical in mediating 
cerebral inflammation after SAH, we next tested whether HO-1 
was involved in clearance of the blood burden after SAH. MRI 
showed 42% greater hematoma volumes in LyzM-Cre-Hmox1fl/fl 
mice compared with those in Hmox1fl/fl control mice (Figure 2, I 
and J). Collectively, these data demonstrate that HO-1 in microglia 
is necessary to eliminate blood and defend against blood-induced 
injury and the development of neurocognitive deficits.
Hematoma volume in aneurysmal SAH patients correlates with 
HO-1 expression. With a role for microglial HO-1 established in 
Figure 3. HO-1–competent BMTx does not influence 
neuronal injury after SAH in mice deficient in 
microglial HO-1. (A) Representative (n = 6) brain tis-
sue sections (original magnification, ×20) depicting 
the prevention of BM-derived cell engraftment into 
the brain 4 weeks after whole-body irradiation (12 
Gy) and transplantation of BM cells from Cx3cr1-GFP 
mice by lead shielding of the head (see Supplemen-
tal Figure 1). (B) Representative (n = 6) macroscopic 
views and microscopic brain tissue sections illus-
trating that head shielding during radiation prevents 
infiltration of BM-derived Cx3cr1-GFP cells into the 
brain 7 days after SAH. Original magnification, ×4 
(2nd row of panels from top) and ×20 (bottom 4 
panels). (C) Representative (n = 6) H&E-stained 
cross sections (original magnification, ×40) of the 
MCA after SAH in LyzM-Cre Hmox1fl/fl chimeras 
(MG-Hmox1–/– MY-Hmox1+/+) and control chimeric 
mice (MG-Hmox1+/+ MY-Hmox1+/+). (D) Quantification 
of MCA vasospasm. *P = 0.0059 (2-tailed Student’s 
t test; n = 6). (E and F) Quantification of TUNEL-pos-
itive cells per microscopic field in the DG (E) and 
cortex (F). *P = 0.0042 (DG) and P = 0.0002 (cortex) 
(2-tailed Student’s t test; n = 6). (G) Number of total 
errors in spatial memory function by Barnes maze 
assessment. *P = 0.0294 (day 2) and **P = 0.0005 
(day 3) (2-way ANOVA; n = 6). (H) Total latency in 
seconds for spatial memory function by Barnes 
maze assessment. *P < 0.0001 for days 1–3 (by 
2-way ANOVA; n = 6).
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PMG was involved in neuronal apoptosis in response to red blood 
cells. Indeed, when HT22 neuronal cells were cocultured with red 
blood cell–treated microglia from LyzM-Cre Hmox1fl/fl mice, neu-
ronal apoptosis measured by TUNEL was significantly increased 
compared with that seen in Hmox1fl/fl control PMG (Figure 6, F and 
G). To confirm that this increase in neuronal apoptosis was due to 
impaired red blood cell phagocytosis, we blocked phagocytosis 
pharmacologically in WT PMG and assessed the amount of neu-
ronal apoptosis by TUNEL staining. Two different phagocytosis 
inhibitors (cytochalasin D and dynasore) significantly increased 
neuronal cell death in response to red blood cell treatment (Figure 
6H). This impairment of red blood cell phagocytosis in WT PMG 
in the presence of the phagocytosis inhibitors, as well as in PMG 
from LyzM-Cre Hmox1fl/fl mice, was also observed by light micros-
copy (data not shown).
CO modulates neuronal injury after SAH by enhancing clearance 
of blood and modulating inflammation. After defining the protec-
tive role of HO-1 in SAH, we next sought to evaluate whether the 
protective effect of HO-1 could be mimicked by exogenous appli-
cation of CO, one of its catalytic products. We first analyzed the 
effect of CO exposure on WT mice subjected to SAH and evaluated 
vasospasm, neuronal apoptosis, and memory function after SAH 
with or without CO. CO gas exposure was started 1 hour after SAH 
and then repeated daily for the duration of the experiment. Ani-
mals treated with CO showed significantly decreased vasospasm 
and neuronal apoptosis in the hippocampus and cortex (Figure 7, 
A–D). Spatial memory function was significantly improved after 
spatial reversal in animals treated with CO compared with those 
exposed to room air (RA) in 2 separate spatial memory tests (Fig-
ure 7, E–G). Finally, hematoma volume measured by MRI in mice 
vation of proinflammatory cytokines including IL-1β, IL-8, and 
TNF-α, but also elevated antiinflammatory IL-10 (Figure 5, G–K). 
Collectively, these data show that sudden accumulation of blood 
into the subarachnoid space in the brain results in an elevation of 
HO-1 expression in the CSF of patients and thus may be an impor-
tant response mechanism in hemorrhage-induced inflammation 
and neuronal cell death.
HO-1 expression in microglia is important in erythrophagocyto-
sis and neuroprotection. Given the MRI results for the LyzM-Cre 
Hmox1fl/fl mice with SAH compared with those for Hmox1fl/fl con-
trols, we surmised that a role for microglial HO-1 in hematoma 
resolution could exist. We hypothesized that erythrophagocytosis 
by microglia required in part HO-1, was critical to neuronal sur-
vival, and explained in part the cognitive dysfunction in mice lack-
ing microglial HO-1. To study this, we isolated primary microglia 
(PMG) from LyzM-Cre Hmox1fl/fl mice and Hmox1fl/fl control ani-
mals, exposed them to fluorescence-labeled red blood cells, and 
analyzed phagocytosis of red blood cells by flow cytometry and 
light microscopy. Compared with PMG from Hmox1fl/fl mice, LyzM- 
Cre Hmox1fl/fl PMG showed less phagocytic activity (Figure 6A). 
The mean fluorescence per cell, indicative of the number of red 
blood cells phagocytosed per microglia, was 36% lower in micro-
glia from LyzM-Cre Hmox1fl/fl mice than in microglia from control 
animals (Figure 6B). We also analyzed erythrophagocytosis by 
light microscopy for visual confirmation of the flow cytometric 
data. The number of red blood cells per PMG and the percent-
age of red blood cell–positive PMG were significantly reduced in 
microglia from LyzM-Cre Hmox1fl/fl mice (Figure 6, C–E).
On the basis of the results described above, we next tested 
whether the impaired phagocytosis observed in LyzM-Cre Hmox1fl/fl 
Figure 4. HO-1 deficiency in neurons and 
astrocytes does not influence neuronal injury 
after SAH. (A) Animals with neuron- and astro-
cyte-specific HO-1 deficiency (Nes-Cre Hmox1fl/fl, 
right panel) showed visible DsRed expression in 
retinal neurons compared with controls (Hmox1fl/fl, 
left panel, representative of 6 mice). DsRed 
expression was exclusively initiated when the 
LoxP site–flanked Hmox1 gene was deleted in 
cells with Nes-Cre gene expression. (B) Quan-
tification of MCA vasospasm, defined as the 
quotient of LR and WL. P = NS (2-tailed Stu-
dent’s t test; n = 6). (C and D) Quantification of 
TUNEL-positive cells per microscopic field in the 
DG (C) and cortex (D). P = NS (2-tailed Student’s 
t test; n = 6). (E) Number of total errors in spatial 
memory function by Barnes maze assessment. 
Graph shows test results on the days after 
spatial reversal. P = NS (2-way ANOVA; n = 9). 
(F) Total latency in seconds for spatial memory 
function by Barnes maze assessment. P = NS 
(2-way ANOVA (n = 9).
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treated with CO after SAH was significantly reduced compared 
with that in animals treated with RA (Figure 7, H and I).
To establish that the effects seen with gaseous CO were not 
specific to the route of delivery, we administered a CO-releasing 
molecule (CO-RM). Intravenous injection of CO-saturated, pegy-
lated hemoglobin (MP4CO) had beneficial effects in the brain 
similar to those observed with inhaled CO when compared with 
control pegylated hemoglobin without CO (Figure 8, A–D).
As sex-specific treatment effects have been observed in vari-
ous brain injury models (34), we also evaluated the effects of CO 
on female mice in our SAH model and found a protective effect of 
CO on vasospasm and neuronal apoptosis comparable to that seen 
in male WT mice (Figure 8, E–H).
CO is a potent antiinflammatory molecule (28). We next tested 
whether CO influenced SAH-induced neuroinflammation, as 
assessed by expression of the astrocytic and microglial activation 
markers GFAP and IBA1, respectively. CO increased IBA1 expres-
sion in SAH mice at the base of the brain and cortex compared with 
that detected in SAH mice exposed to RA (Figure 9A), while GFAP 
reactivity was reduced in all brain regions in SAH animals treated 
with CO (Figure 9B). Microglial activation assessed by morphology 
was altered by SAH, with loss of ramification and thickening of pro-
Figure 5. HO-1 expression and activity are determined by hematoma volume in human SAH patients. (A) Representative (n = 11) CT scan of SAH  
patient obtained within 24 hours of admission. (B) Spearman’s correlation of CSF cellular HO-1 expression of SAH patients (n = 11) versus CHV on day 1.  
r = 0.84 (95% CI: 0.46–0.96); P = 0.0022. (C) Spearman’s correlation for HO-1 expression on day 1 (circles) and day 7 (triangles) versus CSF bilirubin 
content. r = 0.92 (95% CI: 0.80–0.97); P < 0.0001. (D) CSF bilirubin content for SAH patients versus control patients (unruptured cerebral aneurysm). 
*P = 0.0157 for day-7 SAH versus control and #P = 0.0123 for day-7 SAH versus day-1 SAH (1-way ANOVA; n = 11). (E) CSF cellular HO-1 expression after 
SAH versus controls. *P = 0.0029 for day-7 SAH versus control and #P = 0.0012 for day-1 SAH versus control (1-way ANOVA; n = 11). (F) HO-1 expression in 
peripheral blood leukocytes after SAH versus controls. *P = 0.0002 for control versus day-1 SAH and #P = 0.0122 for day-1 SAH versus day-7 SAH (1-way 
ANOVA; n = 11). (G–K) IL-1β (G; *P = 0.0016 for control versus day-7 SAH and #P = 0.0067 for day-1 SAH versus day-7 SAH); IL-6 (H; *P = 0.0123 for control 
versus day-7 SAH); IL-8 (I; *P = 0.0045 for control versus day-7 SAH and #P = 0.0459 for day-1 SAH versus day-7 SAH); TNF-α (J; *P = 0.0451 for control 
versus day-1 SAH and #P = 0.0144 for control versus day-7 SAH); and IL-10 (K; *P = 0.0072 for control versus day-7 SAH) concentrations in CSF compared 
with controls (all by 1-way ANOVA; n = 11).
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cesses, and was unchanged in the presence of CO or RA compared 
with naive controls (Figure 9C). These data demonstrate that similar 
to the in vitro studies, CO enhances hematoma clearance and modu-
lates neuroinflammation in vivo and does so irrespective of sex.
HO-1 deficiency can be rescued with inhaled CO. After showing 
that CO was effective in reducing neuronal injury after SAH, we 
next asked whether exogenous application of CO could recapitu-
late the neuroprotective effects in microglia lacking HO-1 in vivo. 
We exposed animals treated with SnPP, as well as cohorts of LyzM- 
Cre Hmox1fl/fl mice, to CO (250 ppm) following SAH. SnPP- 
injected SAH mice treated with CO showed less vasospasm and 
neuronal apoptosis than did animals injected with SnPP alone 
Figure 6. Importance of microglial HO-1 for erythrophagocytosis and neuronal survival in vitro. (A) Quantification of the percentage of microglia positive 
for fluorescence-labeled (pHrodo) red blood cells by flow cytometric analysis. *P = 0.0015 for Hmox1fl/fl red blood cells versus LyzM-Cre Hmox1fl/fl red blood 
cells (2-tailed Student’s t test; n = 3). (B) Mean fluorescent signal in microglia after exposure to fluorescence-labeled red blood cells. *P = 0.0274 for 
Hmox1fl/fl red blood cells versus LyzM-Cre Hmox1fl/fl red blood cells (2-tailed Student’s t test; n = 3). (C) Representative (n = 3) light microscopic images (orig-
inal magnification, ×40) of Hmox1fl/fl and LyzM-Cre Hmox1fl/fl microglia after exposure to red blood cells. (D) Quantification of red blood cells per microglia, 
analyzed by light microscopy. *P < 0.0001 for Hmox1fl/fl red blood cells versus LyzM-Cre Hmox1fl/fl red blood cells (2-tailed Student’s t test; n = 3). (E) Quanti-
fication of the percentage of red blood cell–positive microglia by light microscopy. *P < 0.0001 for Hmox1fl/fl red blood cells versus LyzM-Cre Hmox1fl/fl  
red blood cells (2-tailed Student’s t test; n = 3). (F) Representative images (original magnification, ×20; n = 3) from TUNEL staining (red) of neuronal cells 
cocultured with Hmox1fl/fl or LyzM-Cre Hmox1fl/fl microglia with or without red blood cells. Cell nuclei were counterstained with Hoechst 33258 (blue). (G) 
Quantification of TUNEL-positive neuronal cells per microscopic view. *P < 0.0001 for Hmox1fl/fl red blood cells versus LyzM-Cre Hmox1fl/fl red blood cells 
(2-tailed Student’s t test; n = 3). (H) Quantification of TUNEL-positive neuronal cells per microscopic view. Neuronal cells were cocultured with WT PMG 
treated with the indicated pharmacological inhibitors of phagocytosis. *P < 0.0001 for red blood cells without inhibitor versus red blood cells plus cytocha-
lasin and versus red blood cells plus dynasore (1-way ANOVA; n = 3).
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cytometry and visual counting. The impaired erythrophagocytosis 
observed in PMG from LyzM-Cre Hmox1fl/fl mice compared with 
that in control PMG was rescued when cells were exposed to CO 
(Figure 11, A–E). As a consequence of these observations of phago-
cytosis, we next hypothesized that the ability of the PMG to phago-
cytose erythrocytes would dictate the susceptibility of neurons to 
red blood cell–induced cell death. In Transwell experiments, LyzM- 
Cre Hmox1fl/fl PMG were cocultured with HT22 neuronal cells. 
Fresh erythrocytes were added to the PMG, and neuronal cell 
death was measured by TUNEL staining. Lack of HO-1 in PMG 
resulted in enhanced neuronal cell death, which could be res-
cued with CO exposure (Figure 11, F and G). We concluded from 
these data that PMG become activated by exposure to erythro-
cytes and secrete mediators that in turn cause neuronal apoptosis. 
The protective effects of CO in this setting may be explained by 
an increased phagocytic ability of PMG and possibly a reduction 
in factors that induce neuronal apoptosis. Alternatively, CO may 
directly affect neuronal survival.
(Figure 10, A–C). Similar rescue effects of CO on vasospasm and 
apoptosis were also observed in LyzM-Cre Hmox1fl/fl mice com-
pared with Hmox1fl/fl controls (Figure 10, D–F). Importantly, CO 
was able to reverse the loss in spatial memory observed in SnPP-
treated and LyzM-Cre Hmox1fl/fl mice (Figure 10, G–J). On the basis 
of these results, we concluded that CO generation was a critical 
neuroprotective product of heme metabolism and that the abil-
ity of microglia to generate CO was necessary for effective blood 
clearance and therein a reduction in neuronal injury after SAH. 
Importantly, these data suggest that exogenous CO can in part 
recapitulate the endogenous protective effects of HOs after SAH.
CO enhances microglial erythrophagocytosis to prevent neuronal 
apoptosis. To further corroborate the in vivo findings, we next stud-
ied the effect of CO exposure on erythrophagocytosis in the pres-
ence and absence of HO-1 in PMG in vitro. PMG were loaded with 
pHrodo Green, which measures phagocytosis by a pH-dependent 
fluorescent signal. PMG were exposed to fresh erythrocytes, and 
changes in the pHrodo signal were measured over time by flow 
Figure 7. Exogenous CO gas treatment reduces neuronal injury after SAH in WT mice. (A) Representative (n = 6) H&E-stained cross sections (original 
magnification, ×40) of the MCA 7 days after SAH in WT mice treated with RA or CO. (B) Quantification of MCA vasospasm, defined as the quotient of LR 
and WL. *P = 0.024 for SAH plus RA versus SAH plus CO (2-tailed Student’s t test; n = 6). (C and D) Quantification of cleaved caspase-3–positive cells per 
microscopic view in the DG (C; *P = 0.0382) and cortex (D; *P = 0.0323) for SAH plus RA versus SAH plus CO (2-tailed Student’s t test; n = 6). (E) Number 
of total errors in spatial memory function by Barnes maze assessment. Graphs show test results on the days after spatial reversal. *P = 0.022 (day 0) for 
SAH plus RA versus SAH plus CO and **P = 0.0155 (day 2) (2-way ANOVA; n = 9). (F) Total latency in seconds for spatial memory function by Barnes maze 
assessment. *P = 0.0014 (day 2) and **P = 0.0417 (day 3) (2-way ANOVA; n = 9). (G) Total latency in seconds for spatial memory function by Morris water 
maze assessment. *P = 0.0005 (day 0); **P = 0.0054 (day 1); ***P = 0.0012 (day 2); and #P = 0.0479 (day 3) (2-way ANOVA; n = 9). (H) Representative  
(n = 3) MRIs of mice with intracranial injection of gadopentetate dimeglumine–labeled blood with or without CO treatment. (I) Quantification of radio-
graphically assessed hematoma volume in mice treated with RA or CO. *P = 0.0277 (2-tailed Student’s t test; n = 3).
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ducible isoform HO-2 is exclusively expressed in neurons and 
not upregulated after SAH further emphasizes the specific role 
of microglial HO-1 (14, 16). It also suggests that HO-derived 
CO reaches defined intracellular and intracompartmental con-
centrations that are not immediately compensated for by CO 
production occurring in adjacent cells. Neuronal HO-2 expres-
sion is important for neuronal resistance against excitotoxicity 
(45), traumatic brain injury (46), and neurotransmission (47). A 
role for HO-1 in neurons and astrocytes has not yet been elu-
cidated. Using novel microglia-specific and neuron- and astro-
cyte-specific HO-1–KO mice, we provide evidence that, unlike 
microglial HO-1, neither neuronal nor astrocytic HO-1 plays 
a critical role in altering vasospasm, neuronal injury, or spa-
tial memory after SAH in vivo. Neuronal and astrocytic HO-2 
expression have not been studied, but our data suggest that 
they do not compensate for microglial HO-1 deficiency. Our 
results from the chimera experiments with HO-1–deficient, 
brain-resident microglia and HO-1–competent peripheral leu-
kocytes (MG-Hmox1–/– MY-Hmox1+/+) underscore the notion that 
the effects we observed are specifically due to microglial HO-1 
expression or the lack thereof and not to a contribution of infil-
trating peripheral leukocytes. The fact that no effect was seen 
when HO-1 was deleted in astrocytes and neurons further sup-
ports the specific role of microglial HO-1 in response to SAH.
Discussion
Results obtained in this study demonstrate that microglial HO-1 
expression is essential in the response to SAH by mediating clear-
ance of blood in the subarachnoid space. Central to the beneficial 
effects of HO-1 are the elimination of the pro-oxidant heme bur-
den as well as the generation of CO, which in turn regulates ery-
throphagocytosis. What cannot be overlooked is the added benefit 
of direct effects of CO on neuronal survival in vitro and in vivo due 
to the potent antiapoptotic effects ascribed to CO (29, 35, 36).
HO-1 induction represents an evolutionarily conserved 
response to cellular stress that, when activated, offers benefi-
cial effects in numerous injury models, including the brain (8, 
10). While the role of HO-1 has been well studied in the brain, 
most of the reports have focused on the vasoactive properties 
of HO-1 and less on neuroinflammation (37). Though several 
groups have shown that HO-1 is expressed in microglia after 
SAH and other forms of cerebral injury (14, 16, 17, 38–40), the 
exact role of HO-1 in microglia has not been defined. In this con-
text, it is interesting to note that HO-1 likely possesses cellular 
functions beyond its catalytic role in heme degradation. Distinct 
subcellular localizations and posttranslational modifications 
suggest that the catalytically inactive form of HO-1 serves as a 
transcriptional regulator for an array of genes important in the 
response to oxidative stress (41–44). The fact that the nonin-
Figure 8. Alternative delivery of CO via pegylated hemoglobin and effect of CO in female mice. (A) Representative (n = 6) H&E-stained cross sections 
(original magnification, ×40) of the MCA after SAH in WT mice treated with CO-saturated, pegylated hemoglobin (MP4CO) or pegylated hemoglobin with-
out CO (αHb). (B) Quantification of MCA vasospasm, defined as the quotient of LR and WL. *P = 0.0392 for SAH versus SAH plus αHb and **P = 0.0127 for 
SAH plus αHb versus SAH plus MP4CO (1-way ANOVA; n = 6). (C and D) Quantification of TUNEL-positive cells per microscopic field in the DG (C) and cortex 
(D). (C) *P = 0.0018 for SAH plus MP4CO versus SAH plus αHb and #P = 0.0003 for SAH plus MP4CO versus SAH (1-way ANOVA; n = 6). (D) *P = 0.0009 for 
SAH plus MP4CO versus SAH plus αHb and #P = 0.0001 for SAH plus MP4CO versus SAH (1-way ANOVA; n = 6). (E) Representative (n = 6) H&E-stained 
cross sections (original magnification, ×40) of the MCA after SAH in female WT mice treated with CO gas. (F) Quantification of MCA vasospasm, defined 
as the quotient of the LR and WL. *P = 0.0051 (2-tailed Student’s t test; n = 6). (G and H) Quantification of TUNEL-positive cells per microscopic field in the 
DG (G; *P = 0.0196) and cortex (H; *P = 0.0038) (2-tailed Student’s t test; n = 6).
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ble for phagocytosis and elimination of rogue erythrocytes after 
SAH. Additionally, CO produced by microglial HO-1 is ultimately 
responsible for the preservation of neuronal health via increased 
phagocytic ability, resulting in a decreased cerebral heme burden. 
Controversy remains as to whether resident microglia represent a 
“closed” population within the brain and whether they are able to 
expand and migrate without recruitment and replacement from 
the BM (33, 62). It likely depends on the type of injury and the 
degree to which the BBB becomes compromised as well as on the 
plasticity of the microglial populations (63). Our findings show 
that BM-derived cells do not enter the brain unless there is signifi-
cant impairment of the BBB. More important, animals subjected 
to SAH showed no significant mobilization of systemic leukocytes 
into the brain, indicating preservation of BBB integrity or lack of a 
chemoattractant surge. These data suggest that resident microglia 
remained a “closed” population that was solely responsible for the 
responses to the blood burden we observed.
The exact mechanisms of how the HO-1/CO axis modulates 
erythrophagocytosis by microglia remain to be elucidated. Red 
cells and the cellular components are recognized by a series of 
cognate receptors including CD163, CD36, and TLR4 (64–66). 
SAH is a type of stroke that affects approximately 40,000 
people in the US each year, with an incidence of up to 10 per 
100,000 per year (48, 49). Thirty to forty percent of patients 
will suffer long-term cognitive deficits secondary to delayed 
cerebral ischemia (DCI) (50). It has been a longstanding doc-
trine that the cognitive impairment seen after SAH is primarily 
attributable to vasospasm (51–53). However, recent clinical tri-
als have failed to show beneficial effects when vasospasm was 
effectively ameliorated (54). These findings indicate that vaso-
spasm is likely a marker of disease severity in SAH rather than a 
direct cause of DCI (55). It has become increasingly recognized 
that neuronal inflammation is a major contributor to DCI and 
subsequent neuronal impairment (56, 57).
The role of microglia in neuronal injury is a double-edged 
sword in that these cells can induce neuronal apoptosis via the 
triggering of an inflammatory response (58) but can also result 
in neuroprotection, which is not unlike macrophages in other tis-
sues (59–61). The question as to which fate neurons will take in 
response to activated microglia most likely depends on the eti-
ology of the injury. Here, we define a new role for microglia in 
response to SAH. Microglia are the principal cell type responsi-
Figure 9. Gliosis in response 
to SAH with or without CO. (A) 
Representative images (n = 6) 
depicting IBA1 reactivity (red) in 
different brain regions following 
SAH with or without CO (original 
magnification, ×20; blue shows 
nuclear counterstaining with 
Hoechst 33258). (B) Represen-
tative images (n = 6) depicting 
IBA1 reactivity in different brain 
regions following SAH with or 
without CO (original magnifica-
tion, ×20; blue shows nuclear 
counterstaining with Hoechst 
33258). (C) Detailed microscopic 
images of IBA1-stained brain 
sections (n = 6) showing the 
change in microglial morphology 
in response to SAH, with or with-
out CO, at the base of the brain/
blood injection site (original 
magnification, ×40).
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Importantly, our findings are translated to and corroborated in 
patients in whom we observed that SAH signals to the periphery, 
resulting in elevated HO-1 in peripheral leukocytes. This could also 
be unrelated to brain injury and reflect peripheral events related 
to the patient’s status. HO-1 has been shown to be important in 
the recruitment and migration of BM progenitors in other organs 
(68). Whether peripheral HO-1 is involved in the response to injury 
in the brain, or reflects a more general systemic stress response, 
remains to be determined. While our clinical data support a poten-
tial role for HO-1 in human SAH, as evidenced by a significant 
Whether one or more of these receptors is involved in phagocy-
tosis and blood clearance has not been evaluated. It is also impor-
tant to note that it remains an unsolved question whether exoge-
nous delivery of CO equals the distinct intracompartmental and 
subcellular concentrations of CO produced endogenously via 
HO and whether exogenous CO can fully substitute for the lack 
of endogenous production. However, endogenous and exogenous 
CO provided comparable protection in our SAH model, and others 
(67) have shown that endogenous and exogenous CO has similar 
effects on mitochondrial respiration.
Figure 10. CO rescues increased neuronal injury due to HO-1 deficiency. (A) Quantification of MCA vasospasm, defined as the quotient of LR and WL.  
*P = 0.0097 for SAH plus SnPP versus SAH plus SnPP plus CO (2-tailed Student’s t test; n = 6). (B and C) Quantification of TUNEL-positive cells per micro-
scopic view in the designated brain regions. *P = 0.0281 for the DG (B) and *P = 0.0112 for the cortex (C) for SAH plus SnPP versus SAH plus SnPP plus CO 
(2-tailed Student’s t test; n = 6). (D) Quantification of MCA vasospasm. *P = 0.0014 for SAH LyzM-Cre Hmox1fl/fl versus SAH LyzM-Cre Hmox1fl/fl plus CO 
(2-tailed Student’s t test; n = 6). (E and F) Quantification of TUNEL-positive cells per microscopic view in the DG (E; *P = 0.0016) and cortex (F; *P = 0.0093) 
for SAH LyzM-Cre Hmox1fl/fl versus SAH LyzM-Cre Hmox1fl/fl plus CO (2-tailed Student’s t test; n = 6). (G) Number of total errors in spatial memory function 
by Barnes maze assessment. *P = 0.0301 (day 2) for SAH plus SnPP versus SAH plus SnPP plus CO (2-way ANOVA; n = 9). (H) Total latency in seconds 
for spatial memory function by Barnes maze assessment. *P = 0.0006 (day 2) and **P = 0.0301 (day 3) for SAH plus SnPP versus SAH plus SnPP plus CO 
(2-way ANOVA; n = 9). (I) Number of total errors in spatial memory function by Barnes maze assessment. *P = 0.0231 (day 1) and **P = 0.0246 (day 3) for 
SAH LyzM-Cre Hmox1fl/fl versus SAH LyzM-Cre Hmox1fl/fl plus CO (2-way ANOVA; n = 9). (J) Total latency in seconds for spatial memory function by Barnes 
maze assessment. *P = 0.0233 and **P = 0.0003 for SAH LyzM-Cre Hmox1fl/fl versus SAH LyzM-Cre Hmox1fl/fl plus CO (2-way ANOVA; n = 9).
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(stock 004781; The Jackson Laboratory). Cell-specific HO-1 KO in 
astrocytes and neurons (Nes-Cre Hmox1fl/fl) was achieved by cross-
ing Hmox1fl/fl mice with mice expressing Cre recombinase under 
the nestin (Nes) promoter (stock 003771; The Jackson Laboratory). 
Hmox1fl/fl mice served as the controls for experiments involving 
LyzM-Cre Hmox1fl/fl and Nes-Cre Hmox1fl/fl mice. CX3cr1-GFP mice 
(B6.129P-Cx3cr1tm1Litt/J, stock 005582) and WT animals with a CD45.1 
allele (B6.SJL-Ptprca Pepcb/BoyJ, stock 002104) were purchased from 
The Jackson Laboratory. Animals were fed a standard rodent diet ad 
libitum while kept on a 12-hour light/12-hour dark cycle. All surgical 
procedures and manipulations were performed under general anes-
thesia with ketamine (10 mg/kg) and xylazine (4 mg/kg) and body 
temperature maintenance. At surgery, buprenorphine (50 μg/kg) was 
applied s.c. to treat possible pain.
SAH stroke model. SAH in 10- to 12-week-old mice was achieved by 
prechiasmatic injection of autologous blood. In brief, after induction 
of anesthesia, the head was fixed in a stereotactic apparatus. With a 
midline incision, the skin overlying the anterior skull was opened. A 
correlation between HO-1 expression, inflammatory milieu, and 
CHV, our data do not allow us to draw any conclusion regarding 
HO-1 and clinical outcome after SAH because of the small sam-
ple size. Moreover, we must consider that the elevated bilirubin 
levels detected in the CSF reflect total HO activity (Hmox1 and 
Hmox2) and may involve other cell types in the brain where heme 
catabolism is occurring, leading to bilirubin accumulation in the 
CSF. However, given the potent effects of CO in our mouse model 
of SAH, further clinical investigation is warranted. In the future, 
inhaled CO might be a potential treatment for patients diagnosed 
with this devastating form of hemorrhagic stroke.
Methods
Animals and anesthesia. Male or female C57BL/6 mice were obtained 
from The Jackson Laboratory (stock 000664). Cell-specific HO-1 KO 
in microglia (LyzM-Cre Hmox1fl/fl) was achieved by crossing Hmox1fl/fl 
mice (stock RBRC03163; RIKEN BioResource Center) with mice 
expressing Cre recombinase under the lysozyme (LyzM) promoter 
Figure 11. CO rescues HO-1 deficiency and 
impaired erythrophagocytosis, leading to 
increased cell death in vitro. (A) Quantification of 
the percentage of microglia positive for fluores-
cence-labeled red blood cells by flow cytometric 
analysis. *P = 0.0013 for LyzM-Cre Hmox1fl/fl red 
blood cells versus LyzM-Cre Hmox1fl/fl red blood 
cells plus CO (2-tailed Student’s t test; n = 3). (B) 
Mean fluorescent signal in microglial cells after 
exposure to fluorescence-labeled red blood cells. 
*P = 0.0154 for LyzM-Cre Hmox1fl/fl red blood cells 
versus LyzM-Cre Hmox1fl/fl red blood cells plus CO 
(2-tailed Student’s t test; n = 3). (C) Representa-
tive light microscopic images (original magnifica-
tion, ×40; n = 3) of LyzM-Cre Hmox1fl/fl microglia 
after exposure to red blood cells with or without 
CO. (D) Quantification of red blood cells per micro-
glia, analyzed by light microscopy. *P < 0.0001 for 
LyzM-Cre Hmox1fl/fl red blood cells versus LyzM- 
Cre Hmox1fl/fl red blood cells plus CO (2-tailed 
Student’s t test; n = 3). (E) Quantification of the 
percentage of red blood cell–positive microglia by 
light microscopy. *P = 0.0107 for LyzM-Cre  
Hmox1fl/fl red blood cells versus LyzM-Cre Hmox1fl/fl  
red blood cells plus CO (2-tailed Student’s t test; 
n = 3). (F) Representative images (original mag-
nification, ×20; n = 3) of TUNEL staining (red) of 
neuronal cells cocultured with LyzM-Cre Hmox1fl/fl  
microglia with or without red blood cells and CO. 
Cell nuclei were counterstained with Hoechst 
33258 (blue). (G) Quantification of TUNEL-posi-
tive neuronal cells per microscopic view.  
*P < 0.0001 for LyzM-Cre Hmox1fl/fl red blood cells 
versus LyzM-Cre Hmox1fl/fl red blood cells plus CO 
(2-tailed Student’s t test; n = 3). 
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acquisition phase. Prior to SAH, spatial acquisition was performed for 
7 days, with 3 trials per animal per day. Each animal was started from 
3 different locations each day, represented by the 3 quadrants of the 
maze where the platform was not placed. The order of the starting 
positions was rotated daily. The time limit per trial was set to 1 minute, 
and the inter-trial interval was 5 minutes for each animal. Once the 
animal reached the platform, it was allowed to sit on the platform for 
15 seconds. Animals that did not reach the platform within 1 minute 
were guided toward it. As a surrogate for cognitive function, the 
total time required for the mouse to find the platform (latency) was 
measured. After 7 days of acquisition, SAH and CO treatments were 
administered as described above. Spatial memory testing, which con-
sisted of 1 trial per animal per day, was started on day 1 after SAH and 
continued for 7 days. To test for the ability to extinguish the initial 
learning and acquire memory for a new platform position, the loca-
tion of the platform was moved to the quadrant on the opposite side 
of the maze on day 4 (spatial reversal), while visual cues were kept at 
the initial position. An investigator blinded to treatment groups per-
formed the maze procedures.
H&E staining and evaluation of cerebral vasospasm. Seven days after 
SAH, animals were deeply anesthetized with ketamine and xylazine 
and transcardially perfused with TBS using a peristaltic pump at a flow 
rate of 3 ml/minute. Brains were removed and postfixed in 4% PFA 
for 18 hours. After cryoprotection in sucrose, brains were frozen, cut in 
9-μm sections, and stained with H&E. Representative digital images 
of 3 consecutive middle cerebral artery (MCA) cross sections from 
each animal were obtained, and the lumen radius/wall thickness ratio 
was quantified to assess vasospasm using ImageJ software (NIH).
IHC and TUNEL staining. Frozen brains were cut in 9-μm serial 
coronal sections. Sections were post-fixed with 2% PFA for 10 minutes 
and permeabilized with 0.5% Triton X-100/PBS for 10 minutes. Slides 
were then blocked in horse serum (7% in PBS) for 30 minutes at room 
temperature. Staining was performed with primary antibodies against 
cleaved caspase-3 (1:100; catalog 9664; Cell Signaling Technology) 
and NeuN (1:200; catalog MAB377; EMD Millipore) at 4°C overnight. 
Sections were then conjugated with their corresponding secondary 
antibody for fluorescence (1:600 Alexa Fluor 488 donkey anti-mouse 
and 1:300 Alexa Fluor 594 donkey anti-rabbit; Invitrogen). Nuclear 
counterstaining was done with Hoechst 33258 (1:10,000; 3 min; Sig-
ma-Aldrich), and slides were examined under a fluorescence micro-
scope. To achieve appropriate consistency in cell quantification, 3 
images were obtained for each area of interest to quantify positive 
cells. Quantification was performed in a standardized fashion. Tissue 
sections were obtained 1.5–1.9 mm dorsal from the bregma as deter-
mined by a stereotactic mouse atlas. The subregions of the anterior 
hippocampus (cornu ammonis and DG) and adjacent cortex were ana-
lyzed for neuronal apoptosis.
For TUNEL staining, slides were fixed in 4% PFA for 20 minutes 
and permeabilized with 0.1% Triton X-100 for 2 minutes. After wash-
ing with PBS, sections were covered with enzyme and label solution 
(In Situ Cell Death Detection Kit, TMR Red; Roche Life Science) for 
1 hour at 37°C in a humidified atmosphere. Nuclear counterstaining 
and quantification were performed as described above.
PMG cell culture and treatment. PMG were isolated from mice at 
P5 to P7 by enzymatic neural dissociation (Papain Neural Dissociation 
Kit; Miltenyi Biotec) and in vitro mixed glia culture. In brief, mouse 
brains were enzymatically dissociated according to the manufac-
burr hole was drilled into the skull 4.5 mm anterior to the bregma with 
a caudal angel of 40° using a 0.9-mm drill. Blood (60 μl) was with-
drawn from a C57BL/6 WT blood donor and injected over a 10-second 
period with a 27-gauge needle advanced through the burr hole at a 40° 
angle until reaching the base of the skull. The needle was left in place 
for 5 minutes to avoid backflow.
SnPP IX, CO gas, and MP4CO/αHb treatment. After SAH, animals 
were randomly assigned to receive treatment with either CO or syn-
thetic air for 1 hour. CO exposure was administered in a custom-made 
gas exposure chamber. Animals had free access to food and water dur-
ing the exposure. CO gas (1%) was mixed with synthetic air to achieve 
250 ppm. CO concentration was monitored continuously throughout 
the application by an infrared gas analyzer. Treatment was started 
immediately after the SAH procedure and repeated every 24 hours for 
7 days. For HO inhibition, animals were injected s.c. with 40 μM/kg 
SnPP IX (Frontier Scientific) daily during the Barnes maze training 
period (see below) and after SAH for 7 days. CO-saturated, pegylated 
hemoglobin (MP4CO, 12 ml/kg) or pegylated hemoglobin without 
CO (αHb, 12 ml/kg) (both supplied by Sangart Inc.) was given via daily 
penile injection for 7 days immediately following SAH.
Barnes maze for spatial learning evaluation. Cognitive function and 
spatial learning was tested on the Barnes maze as described previ-
ously, with minor modification. In brief, the paradigm consisted of a 
white circular platform with a diameter of 90 cm. Along the perime-
ter of the platform, 20 equal-sized holes were located. One hole led to 
a box to which the animals could escape from the open platform. As 
an aversive stimulus, a bright light source was placed above the plat-
form. We introduced an additional reward stimulus by placing food 
in the escape box. Cardboard placards with different visual cues were 
placed around the platform. The location of the escape box and the 
visual cues were kept constant during the initial acquisition period. 
Prior to SAH, the mice underwent spatial acquisition for 7 days, with 
3 trials per animal per day. Animals were allowed to explore the maze 
for 3 minutes. Once they entered the escape box, they were allowed to 
remain in the box for 1 minute. The inter-trial interval was 15 minutes 
for each animal, with extensive cleaning of the platform after each ani-
mal to eliminate olfactory cues. Animals that did not enter the escape 
box within 3 minutes were guided to the correct hole. Surrogates for 
cognitive function were measured: specifically, the total time required 
for the mouse to find the goal box (latency) and the number of holes 
the animal explored before finding the goal box (error number). After 
7 days of acquisition, SAH was performed as described above. Spatial 
memory testing, which consisted of 1 trial per animal per day, was 
started on day 1 after SAH and continued for 7 days. To test for flexibil-
ity and relearning, the location of the goal box was moved 180° from its 
original position on day 4 (spatial reversal), while visual cues were kept 
at the initial position. Maze procedures were performed by an investi-
gator blinded to the genotype and treatment groups.
Morris water maze test for spatial learning evaluation. As a sec-
ond test for spatial learning performance, we used the Morris water 
maze test as described previously, with minor modification. In brief, 
a white circular tank with a diameter of 120 cm and a height of 50 cm 
was filled with opaque water. A circular platform with a diameter of 
12 cm was submerged 1 cm below the water’s surface and placed in a 
specific quadrant of the maze. Around the maze, we placed cardboard 
placards depicting different objects as distant visual cues. The loca-
tion of the platform and the visual cues were kept constant during the 
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added to the PMG-containing upper chamber of the coculture, set up 
at concentrations of 10 μM cytochalasin and 50 μM dynasore. TUNEL 
staining of the HT22 was done as described above. Quantification of 
TUNEL-positive cells was performed by capturing 3 representative 
images per coverslip and calculating the percentage of TUNEL-posi-
tive cells to account for differences in cell density. PMG were stained 
with antibodies against IBA1 and TER119 to assess phagocytosis 
by fluorescence microscopy.
In vivo hemorrhage imaging. For hemorrhage imaging, blood 
labeled with gadopentetate dimeglumine was injected into the sub-
arachnoid space as described above. Animals were then treated with 
CO (250 ppm) or RA for 1 hour (WT experiment only), and T1-weighted 
images were acquired on a 9.4 Tesla MRI 8 hours after SAH (n = 3 per 
group). The hematoma volume was calculated using OsiriX software 
as follows: the hematoma area in 3 adjacent sagittal slices (0.5 mm 
slice thickness) in both directions from the midline sagittal (6 slices 
total per animal) was measured and the volume calculated using the 
measured areas and the known slice thickness.
Human sample collection and analysis. CSF and blood samples were 
acquired from consecutive SAH patients admitted to the neuro-ICU 
on days 1 and 7 and from patients with unruptured cerebral aneurysms 
(controls). RNA from CSF cells was isolated with TRIzol, concentrated 
by spin-column purification (RNeasy Micro Kit; QIAGEN), and cDNA 
libraries were acquired by reverse transcription (iScript cDNA Synthe-
sis Kit; Bio-Rad). Gene expression of HO-1 was analyzed by real-time 
PCR (SYBR Green Master Mix; Agilent Technologies), with Rpl13a 
used as a reference gene.
Primer sequences were as follows: HO-1, forward: GTGATAGAA-
GAGGCCAAGACTG, reverse: GAATCTTGCACTTTGTTGCTGG; 
and Rpl13a, forward: CGCTGTGAAGGCATCAACATTTC, reverse: 
GCTGTCACTGCCTGGTACTTC.
Bilirubin, hemoglobin, and protein content in the CSF was ana-
lyzed by spectrometry as described previously (69). In brief, absor-
bance at 340, 415, and 460 nm was measured, and bilirubin (c1), 
hemoglobin (c2), and protein (c3) content was calculated using 
the following formulas:
(a) A340 = 0.012 * c1 + 0.0015 * c2 + 0.000054 * c3
(b) A415 = 0.049 * c1 + 0.0069 * c2 + 0.000016 * c3
(c) A460 = 0.083 * c1 + 0.0006 * c2 + 0.000007 * c3
Blood samples were drawn into RNA-stabilizing tubes (Tempus 
Blood RNA Tubes; Applied Biosystems), and peripheral blood RNA 
was isolated using spin-column purification (Tempus Spin RNA 
Isolation Kit; Applied Biosystems). Gene expression was analyzed 
as described above.
HO-1 expression and bilirubin content in SAH patients were com-
pared with radiographic subarachnoid hematoma volume in the cis-
terns surrounding the pons and the midbrain (CHV, calculated using 
OsiriX software). CHV was calculated as follows: cisternal hematoma 
(specifically, the prepontine cistern, the interpeduncular cistern, and 
the ambient cisterns) areas at the level of the caudal pons extending 
superiorly to the midbrain in 4 adjacent axial CT slices (5 mm slice 
thickness) were measured, and hematoma volumes were calculated 
using the measured areas and the known slice thickness.
Whole-body irradiation with head protection and BM transplanta-
tion. For establishment and validation of the BM transplant (BMTx) 
model, we first performed whole-body irradiation (12 Gy) in WT mice, 
followed by infusion via the penile vein of BM cells (5 × 106 cells/
turer’s instructions, and the resulting mixed glia culture containing 
astrocytes and microglia was cultivated in DMEM containing peni-
cillin-streptomycin, 10% FBS, and M-CSF (10 ng/ml) in a humidified 
atmosphere with 5% CO 2. After 1 week of cultivation, cell culture 
plates were shaken at 200 rpm for 2 hours every 2 to 3 days. Floating 
microglia were collected from the supernatant and seeded onto 6-well 
plates for experiments at a density of 2 × 105 cells per well. Microglial 
phenotype was confirmed by CD11b staining and flow cytometry (see 
below) for every experiment.
For erythrophagocytosis experiments, 100 μl blood was drawn 
from the mandibular vein of a C57BL/6 WT animal, washed with 
PBS, and stained with 35 μM amine-reactive, pH-sensitive fluorescent 
ester dye (pHrodo Green STP Ester; Life Technologies) in 1 ml PBS for 
30 minutes. PMG were incubated with 100 μl labeled red blood cell 
suspension for 1 hour before use. In selected experiments, phagocy-
tosis was blocked with cytochalasin D (10 μM, 30-min pretreatment; 
Sigma-Aldrich) or dynasore (50 μM, 30-min pretreatment; Sigma- 
Aldrich). Cells in which we wanted to study the role of CO were trans-
ferred to an air-tight, humidified chamber (C-Chamber; Biospherix) 
after starting the red blood cell exposure and exposed to 250 ppm 
CO and 5% CO2 for 1 hour, which was controlled by an automated gas 
delivery system (Oxycycler C42; Biospherix).
Light microscopy. After red blood cell exposure, cells were washed 
with PBS 3 times to remove any remaining unphagocytized red blood 
cells. For each well, 3 representative images (original magnification, 
×10) were taken using an inverted light microscope with a camera port 
(Telaval 31; Zeiss). For every image, the number of red blood cells per 
PMG and the percentage of red blood cell–positive PMG were deter-
mined using ImageJ software.
Flow cytometry. After light microscopic analysis, cells were har-
vested with a cell lifter, washed with flow cytometric buffer (PBS 
with 1% BSA, 2 mM EDTA, and 0.05% Na-azide), and stained with 
a PE-Cy7–tagged CD11b antibody (1:100, 30 min; BioLegend). Flow 
cytometry was performed on a FACSCalibur (BD Biosciences), with 
selection of CD11b-positive PMG and detection of phagocytosis- 
related fluorescence in FL-1. The relative percentage of red blood cell–
positive PMG and the mean fluorescence per PMG were calculated 
using FlowJo software.
Western blot analysis. Cells were washed with PBS and lysed 
in radioimmunoprecipitation assay (RIPA) buffer with 1 freeze/
thaw cycle and sonification. Equal amounts of protein were sepa-
rated on a 10% SDS polyacrylamide gel and transferred to a nitro-
cellulose membrane. Membranes were blocked with 5% skim milk 
in Tween-20/TBS and incubated in the recommended dilution of 
specific antibodies (HO-1; 1:1,000; Abcam) overnight at 4°C. Mem-
branes were then incubated with the corresponding secondary anti-
body for infrared fluorescence detection and developed on an Odys-
sey infrared imaging system (LI-COR).
Coculture experiments. Murine hippocampal HT22 cells (gift of 
Joseph Burdo, Biology Department, Boston College, Boston, Massa-
chusetts, USA) were grown in DMEM containing penicillin-strepto-
mycin and 10% FBS. For coculture experiments, cells were plated on 
24-mm coverslips (Neuvitro) at a density of 3 × 105. Coverslips were 
placed into 6-well plates. PMG were plated on 18-mm coverslips (Neu-
vitro), inserted into 3-μM Transwell chambers (EMD Millipore) at a 
density of 1 × 105, and placed onto the HT22 wells immediately before 
the start of the experiment. Blood, with or without inhibitors, was 
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hoc test. Data from spatial memory function testing (Barnes maze, 
water maze) with repetitive measurements on individual animals 
were analyzed using repeated-measures 2-way ANOVA with Bonfer-
roni’s post-hoc test (factor A: time, factor B: genotype or treatment, 
respectively). Correlation was described using Spearman’s correla-
tion coefficient. A P value of less than 0.05 was considered statis-
tically significant. In vivo sample sizes were 6 per group, except for 
behavior experiments (n = 9) and MRI (n = 3). In vitro experiments 
were repeated 3 times. All allocations of animals to experimental 
groups were randomized, as were the in vitro studies. Analysis of 
TUNEL cell counts, vasospasm, in vitro phagocytosis, and hematoma 
volume was done in a blinded manner.
Study approval. All procedures involving animals were approved 
by the IACUC and the Radiation Safety Office (RSO) of Beth Israel 
Deaconess Medical Center. Patients participated in this study under 
a protocol for acquiring CSF and blood samples that was approved by 
the IRB of Beth Israel Deaconess Medical Center and provided writ-
ten informed consent.
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animal) from Cx3cr1-GFP mice (B6.129P-Cx3cr1tm1Litt/J, The Jackson 
Laboratory) on the same day. Cx3cr1-GFP mice showed GFP expres-
sion in all cells expressing Cx3cr1, including most cells emerging 
from the granulocyte-macrophage cell lineage such as macrophages, 
monocytes, microglia, and neutrophils, but also NK cells, DCs, and 
cells of the lymphoid lineage (70–75). In 1 group of animals, the head 
was shielded from radiation with a combined outer lead block (2 cm 
thickness) and inner lead helmet (0.17 cm thickness to shield from 
scattered radiation). One week after transplantation, peripheral blood 
leukocytes were isolated and analyzed for GFP positivity by cytospin-
ning and fluorescence microscopy. A period of 4 weeks was allowed 
for full consolidation of the transplanted BM. GFP positivity of the 
BM was confirmed by flow cytometry at this time point. In addition, 
engraftment of GFP-positive cells into peripheral organs (spleen, liver, 
lung) and the brain, with or without head shielding, was determined 
by fluorescence microscopy. In a separate cohort of animals, SAH was 
induced 4 weeks after transplantation, as described above, to study 
the effect of SAH on the invasion of BM-derived cells into the brain, 
with or without head shielding. Cell invasion into the brain was deter-
mined 1 week after SAH by fluorescence microscopy.
In a second set of experiments, we transplanted 5 × 106 BM cells 
per animal from HO-1–expressing WT animals (B6.SJL-Ptprca Pepcb/
BoyJ, The Jackson Laboratory; this congenic C57BL/6 mouse carries 
the differential CD45.1 allele that allows for transplant detection) 
into LyzM-Cre Hmox1fl/fl (MG-Hmox1–/– MY-Hmox1+/+) and Hmox1fl/fl 
(MG-Hmox1+/+ MY-Hmox1+/+) mice with head shielding. We allowed 
4 weeks for complete BM consolidation before SAH was induced as 
described above. Analysis of vasospasm, neuronal cell death, and spa-
tial memory function was performed as described above.
Statistics. Data were analyzed using GraphPad Prism, version 6 
(GraphPad Software). Results are presented as the mean ± SD. Two 
groups were compared with a 2-tailed Student’s t test, while multiple 
groups were compared using 1-way ANOVA with Bonferroni’s post-
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